par Monchaud, Caroline;de Winter, Brenda C;Knoop, Christiane 
;Estenne, Marc ;Reynaud-Gaubert, Martine;Pison, Christophe;Stern, Marc;Kessler, Romain;Guillemain, Romain;Marquet, Pierre;Rousseau, Annick
Référence Clinical pharmacokinetics, 51, 3, page (175-186)
Publication Publié, 2012-03
;Estenne, Marc ;Reynaud-Gaubert, Martine;Pison, Christophe;Stern, Marc;Kessler, Romain;Guillemain, Romain;Marquet, Pierre;Rousseau, AnnickRéférence Clinical pharmacokinetics, 51, 3, page (175-186)
Publication Publié, 2012-03
Article révisé par les pairs
| Résumé : | Therapeutic drug monitoring of tacrolimus is a major support to patient management and could help improve the outcome of lung transplant recipients, by minimizing the risk of rejections and infections. However, despite the wide use of tacrolimus as part of maintenance immunosuppressive regimens after lung transplantation, little is known about its pharmacokinetics in this population. Better knowledge of the pharmacokinetics of tacrolimus in lung transplant recipients, and the development of tools dedicated to its therapeutic drug monitoring, could thus help improve their outcome. |
